Validation of the Short Form of the Spanish Hypertension Quality of Life Questionnaire (MINICHAL)
Overview
Authors
Affiliations
Background: The finding that low health-related quality of life (HRQoL) can be a risk factor for future cardiovascular events in patients with hypertension emphasizes the need for disease-specific HRQoL assessment tools in this population.
Objective: This study evaluated the feasibility and psychometric properties of the short form of the Spanish Hypertension Quality of Life Questionnaire (MINICHAL).
Methods: An observational, prospective, multicenter study was carried out among patients with hypertension, stratified by sex and disease stage. The feasibility and validity of the MINICHAL were evaluated at baseline. Two follow-up visits were conducted at 1 and 6 months after the initial visit, during which the test-retest reliability and responsiveness to change of the MINICHAL were assessed, respectively.
Results: A total of 736 consecutive patients with hypertension were included. Mean (SD) administration time for the MINICHAL was 7.2 (6.5) minutes. In the validation process, factor analysis showed 2 dimensions: "State of mind" (StM) and "Somatic manifestations" (SM). The response level was high, with 94.3% of patients answering all items. Patients with a higher disease stage (ie, stage II/III hypertension) had a worse HRQoL than those with a lower disease stage (P < 0.01). Internal consistency was 0.87 for StM and 0.75 for SM. Test-retest reliability was 0.82 and 0.75 for the StM and SM dimensions, respectively. Among patients who reported experiencing a positive change in their overall health status 6 months after treatment initiation or treatment change, responsiveness to change ranged from 0.52 (better) to 1.14 (much better).
Conclusions: The MINICHAL questionnaire could be administered in a short time with a high response level and was found to have acceptable psychometric properties. The MINICHAL is a potentially useful tool for the evaluation of HRQoL among patients with hypertension in the routine clinical setting.
Mao Z, Fan J, Rencz F, Yang Z, Luo N, Wang P BMJ Open. 2024; 14(1):e081140.
PMID: 38286698 PMC: 10826542. DOI: 10.1136/bmjopen-2023-081140.
Liu Y, Chang Y, Wan D, Li W, Xu C, Wan C Sci Rep. 2023; 13(1):12935.
PMID: 37558743 PMC: 10412614. DOI: 10.1038/s41598-023-39802-2.
Costa S, Guerreiro J, Teixeira I, Helling D, Pereira J, Mateus C Front Pharmacol. 2022; 13:903270.
PMID: 36160402 PMC: 9493118. DOI: 10.3389/fphar.2022.903270.
Jordan A, Anning C, Wilkes L, Ball C, Pamphilon N, Clark C Health Qual Life Outcomes. 2022; 20(1):39.
PMID: 35246164 PMC: 8895672. DOI: 10.1186/s12955-022-01943-9.
Mantovanil M, Kalinke L, Silva A, Perez Arthur J, Radovanovic C, Bortolato-Major C Invest Educ Enferm. 2021; 39(1).
PMID: 33687808 PMC: 7987286. DOI: 10.17533/udea.iee.v39n1e04.